Status | Study |
Completed |
Study Name: CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma Condition: Peripheral T-Cell Lymphoma Date: 2013-02-25 Interventions: Drug: Alemtuzumab Consolidation after CHOP induction |
Recruiting |
Study Name: Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma Condition: Peripheral T-cell Lymphoma Date: 2013-01-31 Interventions: Drug: Romidepsin + CHOP Ro-CHO |
Completed |
Study Name: A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea Condition: Peripheral T-cell Lymphoma Date: 2012-09-14 Interventions: Drug: SP-02L (darinaparsin for injection) |
Completed |
Study Name: Treatment of Peripheral T-cell Lymphoma Condition: Peripheral T-cell Lymphoma Date: 2012-08-10 Interventions: Drug: GDPT regimen GDPT regime |
Completed |
Study Name: Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) Condition: Peripheral T-Cell Lymphoma Date: 2012-05-30 Interventions: Biological: KW-0761 (mogamulizumab) 1 mg/kg administered intravenously weekly x 4 then every other week |
Completed |
Study Name: A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) Condition: Peripheral T-cell Lymphoma Date: 2011-09-13 Interventions: Drug: SP-02L (darinaparsin for injection) |
Completed |
Study Name: E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma Condition: Peripheral T-Cell Lymphoma Date: 2011-07-18 Interventions: Biological: denileukin diftitox (E7777) E7777 will be administered by intravenous (IV) infusion for 5 da |
Completed |
Study Name: A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas Condition: Peripheral T Cell Lymphoma Date: 2011-01-14 Interventions: Drug: Romidepsin and CHOP Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in co |
Active, not recruiting |
Study Name: Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry Condition: Peripheral T-cell Lymphoma Date: 2010-04-23 |
Completed |
Study Name: Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma Condition: Peripheral T-Cell Lymphoma Date: 2009-04-27 Interventions: Biological: KW-0761 The starting dose will be 0.1 mg/kg administered i.v. once every week for four weeks |